Effient Tablet, Coated
Product Images NDC 0713-0882

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Effient (NDC 0713-0882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cosette Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Effient 01)

This appears to be a table or graph showing the incidence of bleeding events (major or minor) in patients taking Effient and Clopidogrel at various times after randomization. The table also includes the number of patients at risk and the days from randomization.*

FDA Label Image

Chemical Structure (Effient 02)

FDA Label Image

Figure 2 (Effient 03)

FDA Label Image

Figure 3 (Effient 04)

This appears to be a chart indicating the percentage of cardiovascular death, nonfatal MI, or nonfatal stroke over a period of 450 days after randomization in patients receiving Clopidogrel for UA/NSTEMI. There are two sets of data, one labeled "Clopidogrel" with percentages of 12.4% and 13.9%, and one labeled "s" with a percentage of 12.4%. The significance of the label "s" is not available.*

FDA Label Image

Figure 4 (Effient 05)

This is a table showing various baseline characteristics of patients in a study related to UANSTEMI, including their age, gender, weight, medical history, and other demographic information. There is also a mention of the stent type used and GP lbila nhibitor use. The table displays percentages of events and hazard ratios for Effient and Clopidogrel, indicating which drug was more effective for the patients.*

FDA Label Image

Figure 5 (Effient 06)

This appears to be a data table with information on baseline characteristics, percentages, and events related to treatment with two drugs: Effient and Clopidogrel. The data is further broken down by variables such as gender, body weight, region of the world, and previous medical history. The table also includes a comparison of the hazard ratio between the two drugs. Further context and interpretation of the data cannot be determined without additional information.*

FDA Label Image

Principal Display Panel (5 mg Tablet Bottle Label)

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.